Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy in Upper Tract Urothelial Cancer
NCT04574960Phase 3Recruiting
- Sponsor
- University Health Network
- Start
- Feb 2021
- Primary completion
- Dec 2027
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine and Cisplatin micelle injection (HA132) in upper tract urothelial carcinoma (UTUC) (2 arms), sponsored by University Health Network. Primary endpoints: Feasibility of enrolling patients by assessing pilot trial recruitment rates at 24 months, Disease-free survival at 36 months and 1 more. Started Feb 2021; status: recruiting.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT04574960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04574960.